Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
COSINR
Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer
- NCT03223155 ↗
- Active, not recruiting
- University of Chicago
- Standard
We haven't built an HCP commentary report on COSINR (nivolumab and ipilimumab in Stage IV Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on COSINR so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 13 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Stage IV Small Cell Lung Cancer
- Interventions
- Nivolumab; Ipilimumab; Stereotactic body radiation therapy
- Arms
- Sequential Arm · Experimental
- Concurrent Arm · Experimental
- Enrollment
- 78
- Primary outcomes
- Number of serious adverse events
- Sponsor
- University of Chicago
- Start
- Sep 7, 2017
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03223155 · updated Mar 4, 2026
Publications
linked from the registry- Chen D, Wang L, Wen C, Piffko A, Bugno J, Yu X, Wang P, Ji F, Naccasha EZ, Wang J, Huang X, Chmura SJ, Pitroda SP, He C, Liang HL, Weichselbaum RR. Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function. J Exp Med. 2026 Jan 5;223(1):e20250641. doi: 10.1084/jem.20250641. Epub 2025 Nov 6. PubMed 41196643